DIPK2B

Across TCGA pan-cancer cohorts, DIPK2B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DIPK2B data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DIPK2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DIPK2B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where DIPK2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.277	0.783	.007	16	view →
LUAD	DFS	Median	All	0.387	1.000	.031	5	view →
GBM	DFS	Quartile	All	0.874	0.575	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DIPK2B–PDAC (OS)

Open the PDAC breakdown →